Revenue from operations grew by 8.7% year on year to Rs 618.56 crore in the quarter ended 31 March 2023. The growth in the revenue was mainly due to increase in CRAMS revenue from India and Switzerland.

Carbogen Amcis – CRAMS revenue increased by 9.1% YoY in Q4 FY23, primarily due to higher supplies of commercial APIs. Carbogen Amcis – Cholesterol and Vitamin D analogues revenue decreased by 5.3% YoY in Q4 FY23, primarily due to lower sales of Vitamin D analogues.

The company reported loss before exceptional items and tax of Rs 41.98 crore in Q4 FY23 from a loss before exceptional items of Rs 73.16 crore posted in Q4 FY22. The firm recorded an exceptional loss of Rs 45.62 crore during the quarter

Total expenses rose 17.08% YoY to Rs 147.26 crore in Q4 FY23. Cost of materials consumed was at Rs 41.07 crore (down 4.22% YoY) while employee benefits expense stood at Rs 19.50 crore (up 1.88%) during the period under review.

EBITDA zoomed 133.9% to Rs 514.4 crore in the fourth quarter of FY23 as against Rs 219.9 crore in Q4 FY22. EBITDA margin improved to 8.3% in Q4 FY23 as compared to 3.9% registered in the corresponding quarter previous year.

During FY23, the company reported a consolidated net loss of Rs 29.80 crore in FY23 as against a net profit of Rs 18.01 crore posted in FY22. Revenue rose 12.7% YoY to Rs 2,412.92 crore in FY23.

For Q4 FY23 and full year FY23, capital expenditure was around $17.9 million and $68.8 million, respectively.

Dishman Carbogen Amcis is a fully integrated CRAMS (contract research & manufacturing) company. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.